AZD 5153

Drug Profile

AZD 5153

Alternative Names: AZD5153

Latest Information Update: 04 May 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Small molecules
  • Mechanism of Action BRD4-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 04 Jul 2017 AstraZeneca plans a phase I trial for Solid tumours and Lymphoma (Refractory metastatic disease) in USA (NCT03205176)
  • 16 Apr 2016 Preclinical trials in Haematological malignancies in United Kingdom (unspecified route) prior to April 2016
  • 16 Apr 2016 Preclinical trials in Solid tumours in United Kingdom (unspecified route) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top